A Competitive Ligand-binding Assay for the Detection of Neutralizing Antibodies Against XTMAB-16

Frontage develops a full validation of the XTMAB-16 NAb (neutralizing antibody) assay with acceptable drug and target tolerances to guide future clinical trials.

"*" indicates required fields

First Name*

Last Name*

Company*

State*

Country

Email*

Phone*

Please only hit the submit button once.

I AGREE*

By submitting this form I agree that Frontage may process my data in the manner described in Frontage’s Privacy Policy.

Comments

This field is for validation purposes and should be left unchanged.

A Competitive Ligand-binding Assay for the Detection of Neutralizing Antibodies Against XTMAB-16

Resources to Consider

AAIC 2025: Comparison of Plasma pTau217 Assays on Different Platforms

WRIB 2025: Validation of an Ultra-High Sensitive Simoa Assay for the...

WRIB 2025: Innovative Strategy for Overcoming pH-Related Assay...

WRIB 2025: Integrated Non-cell Based and Cell-based NAb Assays for a...

Biomarkers Assay List – July 2025

AAPS 2024: A GxP-Qualified dPCR-Based RCL Assay to Quantify...

Overview of Cell-Free Assay Services

Qualification of the Quanterix Phospho-Tau 217 (pTau-217) assay using...

Quantitative Assessment of mRNA Drug Biological Activity by...

A GxP-Qualified dPCR-Based RCL Assay to Quantify Replication...

Validating Digital Droplet PCR (ddPCR) Assay with Zero-Inflated...

pTau217 Biomarker Assay